The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study-Reference-Cited by-同舟云学术

The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study

Published:2012-06 Issue:6 Volume:14 Page:642-651
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European Journal of Heart Failure

Author:

Ghali Jalal K.¹,Orlandi Cesare²,Abraham William T.³,

Affiliation:

1. Detroit Medical Center Cardiovascular Institute; Detroit MI 48201 USA

2. Cardiokine Biopharma, Inc.; Philadelphia PA USA

3. The Ohio State University; Columbus OH USA

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1093/eurjhf/hfs051/fullpdf

Reference30 articles.

1. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists;Ghali;J Card Fail,2010

2. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy;Stevenson;Am J Cardiol,1990

3. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure;Steimle;Circulation,1997

4. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure;Lucas;Am Heart J,2000

5. Chronic ambulatory intracardiac pressures and future heart failure events;Stevenson;Circ Heart Fail,2010

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risks of vaptans in hypernatremia and serum sodium overcorrection: A systematic review and meta‐analysis of randomised controlled trials;International Journal of Clinical Practice;2020-12-31

2. Comparison of the Hepatotoxic Potential of Two Treatments for Autosomal-Dominant Polycystic Kidney DiseaseUsing Quantitative Systems Toxicology Modeling;Pharmaceutical Research;2020-01-06

3. The New Biology of Diabetic Kidney Disease—Mechanisms and Therapeutic Implications;Endocrine Reviews;2019-10-21

4. Interventions for chronic non-hypovolaemic hypotonic hyponatraemia;Cochrane Database of Systematic Reviews;2018-06-28

5. Spectrofluorimetric methods for the determination of lixivaptan and its hydrolysis product in human plasma and urine, with factors optimization study;Journal of Molecular Liquids;2018-01